相关实验视频

Updated: May 3, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

在肝细胞癌中,HMOX1+巨细胞决定了免疫抑制的微环境和免疫疗法的疗效

Yabing Du¹, Wenxin Xu², Zhenkun Liu¹

¹Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.

Hepatology communications

|October 14, 2025

概括

血氧酶1 (HMOX1) 阳性巨细胞与肝癌 (HCC) 和免疫疗法耐药性的不良结果有关. 向HMOX1可能会改善HCC患者的抗PD-1疗法的有效性.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

肝细胞癌 (HCC) 是一种免疫抑制性恶性瘤,治疗选择有限,预后不佳.
巨细胞是瘤微环境中的关键免疫细胞,影响HCC进展和治疗反应.
识别特定的巨细胞子集对于理解HCC和开发有效疗法至关重要.

研究的目的:

为了识别与HCC进展相关的巨细胞子集.
调查巨细胞在HCC免疫疗法耐药性中的作用.
评估血红氧酶1 (HMOX1) 作为潜在的生物标志物和治疗点在HCC.

主要方法:

单细胞RNA测序和转录组分析以识别巨细胞标记物.
免疫光检测以评估HMOX1+巨细胞在HCK患者中的临床相关性.
通过飞行时间 (CyTOF) 进行细胞计量,以探索HCC免疫微环境和HMOX1+巨的功能.

主要成果:

在HCC中,HMOX1在内巨中高度表达.
高丰度的HMOX1+巨细胞与HCC的更糟糕的预后和降低免疫疗法的有效性有关.
HMOX1+巨细胞有助于免疫抑制瘤微环境,其特点是调节性T细胞和CD8+T细胞上的PD-1表达.
在HCC小鼠模型中,使用Znpp抑制HMOX1增强了抗PD-1疗法的疗效.

结论:

宏细胞特异性HMOX1是一种用于预测HCC免疫疗法疗效的新型生物标志物.
向HMOX1是一个潜在的策略,可以改善HCC患者的抗PD-1治疗结果.

关键词:

在HCC中,HCC是HCC,HCC是HCC.血红氧酶-1-1的使用免疫疗法免疫疗法巨细胞是什么?巨细胞是什么?瘤微环境是一个微环境.

更多相关视频

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...